Meeting
2024 ASCO Annual Meeting
The effect of sodium glucose cotransporter-2 inhibitors on mortality and cardiovascular outcomes of patients with prostate cancer receiving luteinizing hormone releasing hormone agonists.
Authors
Zhiting Tang
Department of Medicine, Unity Hospital, Rochester Regional Health, Rochester, NY
Zhiting Tang , Cho Han Chiang , Yu-Cheng Chang , Xin Ya See , Qian Wang , Kuan-Yu Chi , Cho Hung Chiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptom Science and Palliative Care
Track
Symptom Science and Palliative Care
Sub Track
Cardio-Oncology
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 12025)
DOI
10.1200/JCO.2024.42.16_suppl.12025
Abstract #
12025
Poster Bd #
154
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world analyses of mortality risk after androgen deprivation therapy initiation in Black vs. White patients with prostate cancer.
First Author: Judd W. Moul
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2023 ASCO Annual Meeting
Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the Detroit Research on Cancer Survivors (ROCS) cohort.
First Author: Vidhya Nair
Poster
2023 ASCO Genitourinary Cancers Symposium
Ability of STAR-CAP staging system to prognosticate risk of subsequent therapies after initial treatment of M0 prostate cancer.
First Author: Daeun Sung